TEL AVIV, Israel, May 7, 2020 /PRNewswire/ -- Therapix
Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty,
clinical-stage pharmaceutical company focusing on the development
of cannabinoid-based treatments announces today the appointment of
Prof. Ari Shamiss (M.D., M.P.A.) to
the Company's Board of Directors.
Prof. Shamiss is the outgoing CEO of Assuta Medical Centers, the
largest private hospital network in Israel, and consists of eight hospitals and
medical centers. Prof. Shamiss was the Director of Sheba General
Hospital at Tel Hashomer for 10 years ending in August 2016, and is a co-founder of Assuta Life
Ventures (ALiVe), Prof. Shamiss, is also a board member and
advisory at numerous high-tech companies, and is involved in
numerous global business projects in healthcare technology and
infrastructure.
Prof. Shamiss holds an M.D. from the Technion Institute and an
M.P.A. from Harvard University. He is
certified in internal medicine, hypertension and healthcare
management and he is a Professor of Medicine and Vice Dean at
Ben Gurion University School of
Medicine.
Prof. Shamiss was the Surgeon General for the Israel Air Force
(Col. Ret.) and the Director of its Aeromedical Institute. Prof.
Shamiss is a graduate in excellence of the U.S. Navy Aerospace
Medical Institute.
"We are honored to have Prof. Ari Shamiss be
part of Therapix," said Ascher Shmulewitz, M.D., Ph.D.,
Chairman of Therapix. "Prof. Shamiss has a rare set of skills
that includes a combination of strong clinical, academic, as well
as, business leadership. We are hopeful that his knowledge and
experience in the healthcare system can help bring the company's
unique and leading technology to the market."
"I have followed Therapix for several years and I look forward
to be a part of the organization," said Prof. Shamiss. "Therapix's
technology has the potential to create game-changing therapies in
several indications."
About Therapix Biosciences (Nasdaq: TRPX):
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in the following drug development programs based on
tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol
(CBD): THX-110 for the treatment of Tourette syndrome and for the
treatment of obstructive sleep apnea; THX-160 for the treatment of
pain; and THX-210 for the treatment of autism spectrum
disorder and epilepsy. Please visit our website for more
information at www.therapixbio.com, the content of which is
not a part of this press release.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, the Company is using forward-looking
statements when it discusses that Prof. Shamiss's knowledge and
experience in the healthcare system can help bring the company's
unique and leading technology to the market, and that Therapix's
technology has the potential to create game-changing therapies in
several indications. Because such statements deal with future
events and are based on the Company's current expectations, they
are subject to various risks and uncertainties and actual results,
performance or achievements of the Company could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
including those discussed under the heading "Risk Factors" the
Company's Annual Report on Form 20-F filed with the SEC on
May 15, 2019, and in subsequent
filings with the U.S. Securities and Exchange Commission. Except as
otherwise required by law, the Company disclaims any intention or
obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result
of new information, future events or circumstances or
otherwise.
Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/therapix-biosciences-appoints-prof-ari-shamiss-md-mpa-to-the-companys-board-of-directors-301055393.html
SOURCE Therapix Biosciences Ltd.